Two Chinese companies were selected as the top 100 global medical devices in 2022

Recently, the medical device industry website Medical Design & Outsourcing released the 2022 global top 100 medical device list, Medtronic, Johnson & Johnson, Siemens ranked in the top three, operating income of 31.
686 billion, 27.
1 billion and 20.
517 billion
, respectively.

A total of 2 Chinese medical device companies were selected, namely Mindray Medical and Minimally Invasive Medical, with total revenue (USD) of 3.
917 billion and 778 million
, respectively.

Mindray Medical Ranking: 32nd Mindray Medical is rapidly sweeping the domestic medical device market through "domestic substitution" and making a strong sound
in the global market.

According to the performance report for the first half of 2022, Mindray Medical's revenue increased by 20.
17% year-on-year to 15.
356 billion yuan
.

In addition, according to fiscal year 2022 revenue, its revenue is about $3.
917 billion
.

In recent years, in the face of new opportunities ushered in by the domestic medical device industry, Mindray Medical has dared to make breakthroughs and continued to increase investment in
research and development.

In 2021, the company invested 2.
726 billion yuan in research and development, more than 10%
of the overall revenue.

At the same time, the company has a rich R & D team, with a total number of employees of 14,600 people
.

It is through continuous high R & D investment, the company's products continue to enrich, technology continues to iterate, especially in the high-end to achieve breakthroughs, to achieve the expansion of low-end to high-end products
.

Minimally Invasive Medical Ranking: 77th Minimally Invasive Medical is famous for cardiac stents
.

In November 2020, the results of the national coronary stent purchase volume were announced, and the average price of coronary stents was reduced from 13,000 yuan to 700 yuan, an average decrease of 93%.


In the context of price reduction, the actions of minimally invasive medical demolition companies have become more and more frequent
.

In August this year, micro-electrophysiology landed on the Hong Kong Stock Exchange's minimally invasive brain science and science and technology innovation board, and as of now, there are five listed subsidiaries
under the "minimally invasive department".

Up to now, minimally invasive medical treatment has made great progress
in the fields of cardiovascular interventional products, orthopedic medical devices, heart rate management, aortic and peripheral vascular intervention products, neurointerventional products, heart valves, surgical robot business, and surgical medical devices.

In the first half of 2022, the company's revenue increased, its aortic and peripheral vascular intervention business of Central Pulse Medical increased by 26.
72% year-on-year, the revenue of neurointervention business of minimally invasive brain science increased by 23.
49% year-on-year, and the heart valve business of Xintong Medical achieved revenue growth of more than two places
.

In fiscal 2022, minimally invasive healthcare revenue is expected to be approximately $778 million
.

The rise of innovative medical devices requires the accumulation of core technologies, and minimally invasive medical research and development investment in the first half of 2022 was 186 million US dollars, an increase of 59.
3%
year-on-year.

The company has 8019 employees
.

Conclusion In recent years, with the expansion of market demand and the continuous optimization of the policy environment, the scale of China's medical device industry has been expanding
.

According to the statistics of the "Blue Book of China's Medical Device Industry (2021)", the market size of China's medical device industry in 2016-2021 has shown an upward trend year by year, and it has approached trillion yuan in 2021, an increase of 20.
22%
year-on-year.

However, the overall level of China's medical device industry compared with the international high level, there is still a significant gap, especially in the high-end field, some core components still rely on imports, domestic enterprises lack bargaining power, so domestic medical device companies also need to strengthen independent innovation and research and development, continue to enhance core competitiveness, and close the gap
with foreign high-end medical devices.

In order to encourage innovation, a series of incentive policies have been introduced at the national level to encourage the innovative development of
domestic medical devices.

Just on September 3, the National Medical Insurance Bureau issued a reply to the outside world, which detailed the mechanisms such as hanging nets and prices of innovative medical devices and the collection and procurement issues, and at the same time clarified that innovative medical devices were not included in the collection and procurement for the time being, providing space
for innovative products to open up the market.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.